Jerusalem, Israel, September 14, 2008 Teva Pharma announced today that following a hearing on September 12, 2008, the U.S. Court of Appeals for the District of Columbia has vacated an April 2008 ruling, which granted Teva 180-day exclusivity for its Risperidone Tablets, AB-rated to Janssen's Risperdal® Tablets. As a result of this decision, the U.S. Food and Drug Administration is no longer enjoined from approving subsequent Abbreviated New Drug Applications (ANDA).
Earlier news of IPPharmadoc on Risperidone Here
(Source: Press release from Teva)
No comments:
Post a Comment